Tag: NOACS

Study shows LAAO reduces major bleeding and mortality compared with NOACs...

Jens Erik Nielsen-Kudsk (Aarhus, Denmark) speaks to Cardiovascular News about a propensity score-matched study which examined left atrial appendage occlusion (LAAO) compared with novel...
atrial fibrillation ablation

ESC 2019: Left atrial appendage closure is non-inferior to NOACS for...

At the 2019 European Society of Cardiology (ESC) Congress (31 August–4 September, Paris, France), Pavel Osmancik (Charles University and University Hospital Kralovske Vinohrady, Prague,...

NOAC therapy leads to increased risk of ischaemic events following TAVI...

The one-year bleeding risk for patients with atrial fibrillation (AF) who undergo transcatheter aortic valve implantation (TAVI) is the same whether they are receiving...

White paper from Heart Rhythm Society suggests Afib treatment has reached...

The Heart Rhythm Society has published a white paper looking at the consequences of oral anticoagulants for managing stroke risk in atrial fibrillation which...
Europe AF 2017

Five surprising messages from this year’s Europe AF

1. The "ILL-CONCEIVED" pallas study may be relaunched John Camm "I want to say just a few quick words about dronedarone", John Camm (St George's University of...

ACC 2017: Uninterrupted dabigatran performs better than warfarin in atrial fibrillation...

Results from the RE-CIRCUIT study have shown that uninterrupted dabigatran (Pradaxa, Boehringer Ingelheim), was associated with fewer bleeding complications than uninterrupted warfarin before, during...

AHA 2016: Low-dose rivaroxaban reduces clinically significant bleeding in PCI patients...

Two drug regimens involving low doses of rivaroxaban (Xarelto, Bayer)—one with a 15mg once daily dose of the drug and a P2Y12 inhibitor and...

Sudden cardiac death is the most common cause of death in...

An analysis from the ENGAGE AF-TIMI 48 trial has found that sudden cardiac death was the single most common cause of death and accounted...